

1 **Assessment of potential transthyretin amyloid cardiomyopathy cases in the**  
2 **Brazilian public health system using a Machine Learning Model**

3 Short title: Assessment of potential transthyretin amyloid cardiomyopathy cases in Brazil  
4 using Machine Learning

5 Author list: Isabella Zuppo Laper<sup>1</sup>; Cecilia Camacho-Hubner<sup>2</sup>; Rafaela Vansan Ferreira<sup>1</sup>;  
6 Claudenice Leite Bertoli de Souza<sup>2</sup>; Marcus Vinícius Simões<sup>3</sup>; Fabio Fernandes<sup>4</sup>; Edileide  
7 de Barros Correia<sup>5</sup>; Ariane de Jesus Lopes de Abreu<sup>1</sup>; Guilherme Silva Julian<sup>2\*</sup>

8 Authors affiliation:

9 <sup>1</sup>IQVIA Brazil, <sup>2</sup>Pfizer Brazil, <sup>3</sup>Cardiologist, Associate Professor of Cardiology at the USP  
10 School of Medicine in Ribeirão Preto. Coordinator of the Amyloidosis Research Center at  
11 HC-FMRPUSP, <sup>4</sup>Cardiologist, Director of the Cardiomyopathies Group at InCor HC-FMU-  
12 SP. Associate Professor of Cardiology at FMUSP, <sup>5</sup>Cardiologist, Head of the  
13 Cardiomyopathies Section and Coordinator of the Amyloidosis Center of Instituto Dante  
14 Pazzanese de Cardiologia

15 \*Corresponding author: Guilherme Silva Julian

16 E-mail for the \*corresponding author: [guilherme.julian@pfizer.com](mailto:guilherme.julian@pfizer.com)

17

18 Author contributions: IZL was responsible for the conceptualization, methodology,  
19 validation, visualization, and writing (original draft preparation). RVF was responsible for  
20 data conceptualization, formal analysis, methodology, validation, and writing (review and  
21 editing). CCH and AJLA were responsible for the conceptualization, supervision, and writing  
22 (review and editing). CLBS was responsible for project administration, supervision, and  
23 writing (review and editing). MVS, FF, and EBC were responsible for validation and writing  
24 (review and editing). GSJ supervised the research and revised the manuscript.

25 **Abstract**

26 **Objectives:** To identify and describe the profile of potential transthyretin cardiac amyloidosis  
27 (ATTR-CM) cases in the Brazilian public health system (SUS), using a predictive machine learning  
28 (ML) model.

29 **Methods:** This was a retrospective descriptive database study that aimed to estimate the frequency  
30 of potential ATTR-CM cases in the Brazilian public health system using a supervised ML model,  
31 from January 2015 to December 2021. To build the model, a list of ICD-10 codes and procedures  
32 potentially related with ATTR-CM was created based on literature review and validated by experts.

33 **Results:** From 2015 to 2021, the ML model classified 262 hereditary ATTR-CM (hATTR-CM) and  
34 1,581 wild-type ATTR-CM (wtATTR-CM) potential cases. Overall, the median age of hATTR-CM  
35 and wtATTR-CM patients was 66.8 and 59.9 years, respectively. The ICD-10 codes most presented  
36 as hATTR-CM and wtATTR-CM were related to heart failure and arrhythmias. Regarding the  
37 therapeutic itinerary, 13% and 5% of hATTR-CM and wtATTR-CM received treatment with  
38 tafamidis meglumine, respectively, while 0% and 29% of hATTR-CM and wtATTR-CM were  
39 referred to heart transplant.

40 **Conclusion:** Our findings may be useful to support the development of health guidelines and policies  
41 to improve diagnosis, treatment, and to cover unmet medical needs of patients with ATTR-CM in  
42 Brazil.

43 **Keywords:** transthyretin amyloid cardiomyopathy; machine learning; predictive model;  
44 Brazilian national health system

## 45 INTRODUCTION

46 Amyloidosis are a group of protein misfolding disorders in which misfolded proteins form  
47 insoluble amyloid fibrils that deposit in the tissues leading to organ damage and dysfunction  
48 (1). Two types of amyloid account for 95% of cardiac amyloidosis: light-chain amyloid (AL)  
49 due to immunoglobulin light-chain deposition and transthyretin (TTR) cardiac amyloidosis  
50 (ATTR-CM), which can be due to hereditary mutation (hATTR) or wild-type transthyretin  
51 (wtATTR) (1). Hereditary transthyretin cardiac amyloidosis (hATTR-CM) is caused by one  
52 of the known heritable (autosomal dominant) mutations in the *TTR* gene, while wtATTR-  
53 CM (also known as senile or senile systemic amyloid CM) is caused by age-related changes  
54 in the wild-type TTR (1). ATTR-CM is an under-recognized cause of heart failure (HF) in  
55 older adults. Although ATTR-CM is considered a rare cardiac disease, recent studies have  
56 shown a prevalence up to 13% of patients hospitalized with HF and preserved ejection  
57 fraction (HFpEF) (2); 16% of patients with aortic stenosis undergoing transcatheter valve  
58 replacement (2); 7–8% of patients undergoing carpal tunnel release surgery (3); and 17% of  
59 older adults with HFpEF in an autopsy series (4). Data on the epidemiology of the disease in  
60 Brazil are scarce, especially in the public health setting.

61 The natural history of ATTR-CM includes progressive HF, complicated by arrhythmias and  
62 conduction system disease. The clinical course is more variable for those with hATTR  
63 compared with wtATTR (1). The hereditary form of the disease usually manifests itself after  
64 the age of 47, with a median survival ranging from 2 to 6 years after diagnosis (depending  
65 on genotype) for untreated patients (1,5–7) due to its low penetrance. On the other hand,  
66 wtATTR-CM is a disease that predominately affects men >60 years of age, with a median  
67 survival ranging from 3.5 to 5 years after diagnosis in untreated patients (depending on the

68 stage of the disease) (1,5–7). Diagnostic delays, which remain common in the current  
69 treatment landscape, are associated with particularly poor prognosis (8). The diagnosis of  
70 ATTR-CM is challenging for several reasons, including the similarity of symptoms with HF,  
71 a prevalent and common disease, especially among older adults, and the unfamiliarity of  
72 clinicians with the disease and its appropriate diagnostic algorithm (1). Misdiagnosis is  
73 common in ATTR-CM, contributing to diagnostic delays and risking both further disease  
74 progression and treatment with ineffective and potentially harmful therapies (9).  
75 Management of cardiac amyloidosis is complex and specific for the type of amyloidosis that  
76 affects the patient. In Brazil, the only treatment approved for ATTR-CM is tafamidis, a TTR  
77 stabilizer that binds the thyroxine-binding sites of TTR with high affinity and selectivity,  
78 slowing dissociation of TTR tetramers into monomers, therefore inhibiting aggregation.  
79 Given the misdiagnosis and significant morbidity of ATTR-CM and availability of treatment  
80 with TTR stabilization, it is essential to identify those ATTR-CM patients who are potentially  
81 under-recognized. Machine learning (ML) models based on medical claims data for the  
82 prediction of diseases and phenotypes have been described in the medical literature with  
83 increasing frequency (10–14). In this way, this study aimed to identify and describe the  
84 profile of potential ATTR-CM in the Brazilian public health system (SUS), using a predictive  
85 machine learning model.

## 86 **METHODS**

### 87 *Study design*

88 This was a database retrospective study that aimed to estimate the frequency of potential  
89 ATTR-CM cases in the Brazilian public health system using a machine learning model. The

90 period of the analysis was from January 1, 2015, until December 30, 2021, in the database.  
91 We conducted the analysis using a supervised machine learning model. The supervised model  
92 uses training datasets that contain information on the desired output (label; true outcome),  
93 i.e., the model learns from labelled training data how to predict the desired outcome. In this  
94 study, labelled data defined “reference ATTR-CM cases” and “not ATTR-CM” cases, based  
95 on criteria set by the investigators. Then, the model predicted among those cases labelled as  
96 “not ATTR-CM” which could be under-recognized ATTR-CM cases (ATTR-CM-like cases)  
97 (Supplementary **Error! Reference source not found.**). The “reference” cases were those  
98 most likely to have a confirmed ATTR-CM diagnosis, while the “like” cases were those most  
99 likely to be under-recognized ATTR-CM cases.

100 The ML approach was performed as follows:

- 101 • “ATTR-CM-reference” cases were defined as:
  - 102 ○ Reference wild-type ATTR-CM (wtATTR-CM): patients aged  $\geq 50$  years old, with  
103 at least one claim with wtATTR-related ICD-10 codes (**Error! Reference source**  
104 **not found.**), AND at least one claim with one of the following cardiac-related ICD-  
105 10 codes: I50.0, I50.1, I50.9, I11.0, I42.0, I42.1, I42.2, I35.0, I44.1, I44.2, I42.5.  
106 (**Error! Reference source not found.**).
  - 107 ○ Reference hATTR-CM: patients aged  $\geq 18$  years old, with at least one claim with  
108 hATTR-related ICD-10 codes (**Error! Reference source not found.**), AND at least  
109 one claim with one of the following cardiac-related ICD-10 codes: I50.0, I50.1,  
110 I50.9, I11.0, I42.0, I42.1, I42.2, I35.0, I44.1, I44.2, I42.5 (**Error! Reference source**  
111 **not found.**).

- 112 • “ATTR-CM-like” cases were those not defined as ATTR-CM in the first step of the ML  
113 approach (*i.e.*, defined as “not ATTR-CM cases”) but classified as ATTR-CM by the  
114 algorithm. For those patients, the criteria set for classification were:
- 115 ○ wtATTR-CM:
    - 116 ■ Patients with at least one claim with any cardiac-related ICD-10 code (**Error!**  
117 **Reference source not found.**) AND at least one claim of the secondary  
118 procedures AND at least one mandatory procedure claim (Supplementary Table  
119 1).
    - 120 ■ Patients with at least one claim with wtATTR-related ICD-10 codes (**Error!**  
121 **Reference source not found.**) AND at least one mandatory OR secondary  
122 procedure (Supplementary Table 1).
  - 123 ○ hATTR-CM: patients with at least one claim with hATTR-related ICD-10 codes  
124 (**Error! Reference source not found.**) AND at least one mandatory OR one  
125 secondary procedure (Supplementary Table 1).

126 **Table 1.** Final International Classification of Diseases (ICD-10) code list for identifying  
127 potential ATTR-CM cases in DATASUS

Hereditary ATTR-CM	
E85.0	Non-neuropathic heredofamilial amyloidosis
E85.1	Neuropathic heredofamilial amyloidosis
E85.2	Heredofamilial amyloidosis, unspecified
Wild-type ATTR-CM	
E85	Amyloidosis
E85.3	Secondary systemic amyloidosis
E85.4	Organ-limited amyloidosis
E85.8	Other amyloidosis
E85.9	Amyloidosis, unspecified
Cardiac-related	
I50.0	Congestive heart failure
I50.1	Left ventricular failure, unspecified

<b>I50.9</b>	Heart failure, unspecified
<b>I51.7</b>	Cardiomegaly
<b>I11.0</b>	Hypertensive heart disease with heart failure (congestive)
<b>I35.0</b>	Aortic valve stenosis
<b>I42.0</b>	Dilated cardiomyopathy
<b>I42.1</b>	Hypertrophic obstructive cardiomyopathy
<b>I42.2</b>	Other hypertrophic cardiomyopathies
<b>I42.5</b>	Other restrictive cardiomyopathy
<b>I44.0</b>	First degree atrioventricular block
<b>I44.1</b>	Second degree atrioventricular block
<b>I44.2</b>	Total atrioventricular block
<b>I44.7</b>	Unspecified left bundle branch block
<b>I47.2</b>	Ventricular tachycardia
<b>I48.0</b>	Flutter and atrial fibrillation
<b>Q25.3</b>	Aortic stenosis
<b>G56.0</b>	Carpal tunnel syndrome
<b>N18.0</b>	Chronic kidney disease
<b>N18.8</b>	Other chronic kidney disease
<b>N18.9</b>	Chronic kidney disease, unspecified

## 128 ***Data sources and feature selection***

129 This study was based on outpatient and inpatient administrative data from DATASUS, the  
130 Informatics Department of SUS, body responsible for collecting, processing, and  
131 disseminating healthcare data in Brazil (15). Two datasets were considered: the Inpatient  
132 Information System (SIH [*Sistema de Informações Hospitalares*]) and Outpatient  
133 Information System (SIA [*Sistema de Informações Ambulatoriais*]). SIH and SIA are  
134 administrative databases for reimbursement purposes (16,17). Due to its administrative  
135 nature, SIH and SIA do not contain clinical data (e.g., signs and symptoms). Thus, cause of  
136 admission (as per International Classification of Diseases (ICD) code) and procedures  
137 performed during the hospitalization were used as predictor variables. Additionally, data  
138 related to patient's age, state of residence, hospitalization, and outpatient visits date,  
139 diagnosis at entry (ICD based), procedures prescribed and performed, and in-hospital length

140 of stay (days) were also extracted.

141 To build the model, a preliminary ICD-10 code list that could be potentially related to ATTR-  
142 CM (i.e., ICD-10 codes most presented or related to ATTR-CM) was created based on  
143 literature review. This list was certified by a group of ATTR-CM Brazilians experts and the  
144 final list with the ICD codes generated is presented at **Error! Reference source not found.**  
145 Different types of procedures were also selected based on the literature review (18,19). Codes  
146 and procedures reference names were collected from the Management System of Procedures,  
147 Medications and OPM of the Unified Health System (SIGTAP), which are the standard  
148 procedures approved within SUS (20). A list of the selected procedures was then validated  
149 by ATTR-CM experts (Supplementary Table 2).

### 150 *Study population*

151 For the wtATTR-CM cohort, were considered patients aged  $\geq 50$  years at index date (date of  
152 first procedure claim related to the ICDs selected as potentially associated with wtATTR-  
153 CM); with wtATTR-CM-related ICD-10 codes and any of the cardiac-related ICD-10 codes  
154 listed in **Error! Reference source not found.** during the study period. And for the hATTR-  
155 CM cohort, were included patients aged  $\geq 18$  years at index date, with hATTR-CM-related  
156 ICD-10 codes during the study period.

157 Patients diagnosed with blood cancers, end-stage renal disease and cerebral amyloid  
158 angiopathy (ICD-10 codes C83.0, C83.3, C85.1, C90.0, C90.1, C88.8, C90.2, C90.3, C88.0,  
159 D47.2, D89.1, E88.0, N18.6 and I68.0) were excluded, minimizing the potential for our  
160 prediction model to overlap with other diseases and forms of cardiac amyloidosis. Also, as a



161 quality step, patients with inconsistent data (e.g., negative age) or with  $\geq 50\%$  of missing data  
162 in the databases were excluded from analysis.

163 This is a modelling study using secondary data from public information sources. In  
164 accordance with the study country regulation, studies using open access and anonymized  
165 databases do not require patient informed consent nor ethics committee approval (21).

### 166 *Linkage methods*

167 Some outpatient databases have unique patient encrypted code (key identifier), while some  
168 other outpatient and inpatient databases do not have it. Because of the lack of patient match  
169 key, a probabilistic record linkage method was used to allow longitudinal assessment using  
170 SIH and SIA, following multiple steps with different combination of patient information  
171 from both databases, such as date of birth, city and ZIP code (22). Before each step, a data  
172 cleaning was performed to keep only good quality claims for linkage. About 5% of all patient  
173 records were discharged from analysis due to low quality information. This approach,  
174 however, enables an assessment of each patient's longitudinal record and thus allowed us to  
175 evaluate their journey across the system.

### 176 *Statistical methods*

177 For the ML model approach, the selected data was separated in train, validation, and test  
178 datasets (Supplementary **Error! Reference source not found.**). During the training step, the  
179 model learned the patterns of the used data. The validation step, then, was used to decide the  
180 most suitable algorithm and the test was the final validation of the model. A supervised  
181 learning algorithm was fitted in the training set to learn the pattern of ATTR-CM and not

182 ATTR-CM cases. We tested three different supervised algorithms (logistic regression,  
183 Support Vector Machine, XGBoost, and Random Forest), so we could choose the one with  
184 the best performance. A K-fold cross validation was performed to get the best model  
185 parameters and control overfitting. After evaluating the result of the best model in the  
186 validation set, it was also evaluated in the test set, to make sure this was the best model. The  
187 machine learning model approach is represented in Supplementary **Error! Reference source**  
188 **not found..** Data analysis was performed considering numerical and categorical variables.  
189 The continuous variables were described as measures of central tendency (mean, median)  
190 and spread, including the range, quartiles, absolute deviation, variance, and standard  
191 deviation, as applicable. The categorical variables were described as counts and percentages.  
192 The age variable was calculated based on the difference between the date of birth and the  
193 first ICD-10 code of interest reported (index date). The age was described as a continuous  
194 variable, including the mean, standard deviation, median and interquartile ranges; and by age  
195 groups (absolute number and proportion per category). The demographic variables were  
196 described as categorical variables, with absolute frequencies and percentage, as well as the  
197 frequency of the selected ATTR-CM-related ICD-10 codes. The proportion of ATTR-CM-  
198 reference and ATTR-CM-like cases among potential ATTR-CM cases in SUS was described  
199 by ATTR-CM type (hereditary and wild-type) per year. The model performance metrics were  
200 also evaluated, considering its accuracy, sensitivity, and specificity. Time of follow-up was  
201 calculated based on the difference between date of first claim of ICD-10 code of interest and  
202 the last date of patient information available at database. The annual hospitalization rate was  
203 described as the number of ATTR-CM-related hospitalizations per 100.000 inhabitants per  
204 each study year. The therapeutic itinerary was presented as the number and proportion of

205 patients with record of tafamidis, heart transplant or liver transplant during the study period.  
206 The resource utilization per patient was summarized as the mean (SD) and median (IQR)  
207 number of hospital admissions and outpatient visits per each patient; and the resource  
208 utilization per patient per year (PPPY) was calculated as the median (95%CI) number of  
209 procedures divided by each patient's follow-up time in years, according to the formula:

$$210 \quad \text{PPPY} = \frac{N_{\text{visits}}}{\text{FUP of each patient (in years)}}$$

## 211 RESULTS

### 212 *Study dataset construction and classification of the ATTR-CM cases*

213 A total of 1,508,468 individuals with claims for the selected ICD-10 codes were identified in  
214 the database from 2015 to 2021. From those, 2,107 (0.14%) were excluded due to blood  
215 cancer, end-stage renal disease or cerebral amyloid angiopathy. Thus, 1,506,361 individuals  
216 were considered to start the construction of the hATTR-CM and wtATTR-CM cohorts  
217 (**Error! Reference source not found.**).

218 Of the 1,506,361 individuals in the initial cohort, 860 were aged  $\geq 18$  years old and had at  
219 least one claim with hATTR ICD-10 codes, composing the hATTR-CM initial dataset. Of  
220 these, 477 hATTR-CM cases were identified from 2015 to 2021, of which 213 were classified  
221 as reference-hATTR-CM and 264 were classified as potential hATTR-CM cases in the first  
222 step of the ML model (**Error! Reference source not found.**). Finally, among those cases  
223 classified as potential hATTR-CM cases in the first step of the algorithm, 49 (10.27%) were  
224 classified as hATTR-CM-like cases and 215 (45.07%) were classified by the ML model as  
225 non hATTR-CM cases (Table 2). That is, the model classified a total of 265 potential

226 hATTR-CM patients (reference and like cases). The prevalence of hATTR-CM among  
227 hATTR patients was 24.8%, considering the 213 reference patients and the 860 individuals  
228 in the initial hATTR cohort.

229 Considering the construction of the wtATTR-CM cohort, 938,385 individuals were aged  $\geq$   
230 50 years old and had at least one claim with wtATTR-CM ICD-10 codes or at least one claim  
231 with cardiac-related ICD-10 codes, being therefore included in the wtATTR-CM initial  
232 cohort. Of these, 203 were classified as reference-wtATTR-CM and 6,177 were classified as  
233 potential wtATTR-CM cases in the first step of the ML model (**Error! Reference source**  
234 **not found.**). In the final step of the ML model, of the 6,177 cases classified as potential in  
235 the first step, 1,378 (21.6%) were classified as wtATTR-CM-like cases and 4,799 (75.22%)  
236 as non wtATTR-CM cases (Table 2). That is, the model classified a total of 1,581 potential  
237 wtATTR-CM patients (reference and like cases). The prevalence of wtATTR-CM cases was  
238 21.6 cases per 100.000 patients  $\geq$  50 years old with cardiac-related ICD-10 codes,  
239 considering the 203 reference patients and the 938,385 individuals in the initial wtATTR-  
240 CM cohort. It is important to notice that this prevalence is based on an initial cohort of  
241 patients with cardiac failure and related diseases, and not on the overall Brazilian population.

242 **Fig 1.** Sample size construction flowchart

243  
244

**Table 2.** Proportion of ATTR-CM-reference and ATTR-CM-like cases in SUS according to the ML model classification from 2015 to 2021

	<b>Total</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>
<b><i>Hereditary ATTR-CM</i></b>	<b>477</b>	<b>39</b>	<b>40</b>	<b>35</b>	<b>23</b>	<b>117</b>	<b>109</b>	<b>114</b>
Classification, N (%)								
hATTR-CM-reference	213 (44.65%)	20 (51.28%)	23 (57.5%)	10 (28.57%)	13 (56.52%)	44 (37.61%)	56 (51.38%)	47 (41.23%)
hATTR-CM-like	49 (10.27%)	3 (7.69%)	5 (12.5%)	4 (11.43%)	0 (0%)	16 (13.68%)	18 (16.51%)	3 (2.63%)
<i>Non-hATTR-CM</i>	215 (45.07%)	16 (41.03%)	12 (30%)	21 (60%)	10 (43.48%)	57 (48.72%)	35 (32.11%)	64 (56.14%)
<b><i>Wild-type ATTR-CM</i></b>	<b>6380</b>	<b>2152</b>	<b>1117</b>	<b>999</b>	<b>774</b>	<b>593</b>	<b>342</b>	<b>403</b>
Classification, N (%)								
wtATTR-CM-reference	203 (3.18%)	107 (4.97%)	20 (1.79%)	24 (2.4%)	20 (2.58%)	17 (2.87%)	9 (2.63%)	6 (1.49%)
wtATTR-CM-like	1378 (21.6%)	578 (26.86%)	264 (23.63%)	194 (19.42%)	140 (18.09%)	94 (15.85%)	60 (17.54%)	48 (11.91%)
<i>Non-wtATTR-CM</i>	4799 (75.22%)	1467 (68.17%)	833 (74.57%)	781 (78.18%)	614 (79.33%)	482 (81.28%)	273 (79.82%)	349 (86.6%)

245 hATTR-CM: hereditary transthyretin amyloid cardiomyopathy; wtATTR-CM: wild-type transthyretin amyloid cardiomyopathy

## 246 *Machine Learning model performance*

247 The final validated model was applied to both hATTR-CM and wtATTR-CM datasets. The  
248 model classified the ATTR-CM cases as reference, potential or not ATTR-CM. For hATTR-  
249 CM cohort, the final validated model predicted 95.35% of hATTR-CM cases and 75.47% of  
250 not hATTR-CM cases and had an accuracy of 84.35% (Table 3). For the wtATTR-CM cohort  
251 (n=6,380), the final validated model predicted 84.62% of wtATTR-CM cases and 77.85% of  
252 not wtATTR-CM cases and had an accuracy of 78.06% (Table 3).

253 **Table 3.** Model performance in final test

<i>Hereditary ATTR-CM</i>	
Accuracy	84.38%
Sensitivity	95.35%
Specificity	75.47%
<i>Wild-type ATTR-CM</i>	
Accuracy	78.06%
Sensitivity	84.62%
Specificity	77.85%

254 Accuracy: the proportion of correct classifications that a trained machine learning model achieves, i.e., the  
255 number of correct predictions divided by the total number of predictions across all classes; Sensitivity:  
256 measures the proportion of true positives that are correctly identified by the model; Specificity: measures the  
257 proportion of true negatives that are correctly identified by the model.

## 258 *Demographic characteristics of ATTR-CM-reference and ATTR-CM-like patients*

259 **Overall, median age of hATTR-CM patients was 66.8 years (interquartile range [IQR]**  
260 **50.5-70.3). In the reference group, median age was 66.8 (IQR 52.8-74.1)**  
261 **years, while in hATTR-CM-like group it was 65.9 (IQR 42.2-71.0). Most**  
262 **patients were over 60 years old over all groups, but a higher proportion of**  
263 **the age group from 30 to 49 years was observed in hATTR-CM-like. There**  
264 **were most males in general (58.8%), as in the reference hATTR-CM**  
265 **(58.2%) and hATTR-CM-like (61.2%) groups (**

266 Table 4).

267 **The median age of wtATTR-CM patients was overall 59.9 years (IQR 55.1-66.3). In**  
268 **the wtATTR-CM reference group, median age was 65.9 (IQR 58.4-73.8)**  
269 **years, while in wtATTR-CM-like group it was 59.2 (IQR 54.8-65.2),**  
270 **demonstrating an opportunity to properly diagnose these potential patients**  
271 **while they're in a less advanced age. Most patients were under 70 years old**  
272 **over all groups, and the wtATTR-CM group had the higher proportion of**  
273 **individuals from 50 to 59 years old (49.1%). Males were the majority**  
274 **overall (62.1%), as well as in the hATTR-CM reference (58.6%) and**  
275 **hATTR-CM-like (62.6%) groups (**

276 Table 4).



**Table 4.** ATTR-CM patients demographic characteristics

	hATTR-CM			wtATTR-CM		
	Total	hATTR-CM reference	hATTR-CM-like	Total	wtATTR-CM reference	wtATTR-CM-like
	262	213	49	1581	203	1378
Age at index date						
Mean $\pm$ SD	61.6 $\pm$ 16.1	62.1 $\pm$ 15.9	59.4 $\pm$ 17.2	61.5 $\pm$ 8.3	66.7 $\pm$ 10.2	60.7 $\pm$ 7.6
Median (min - max)	66.8 (19.3 - 89.3)	66.8 (19.3 - 89.3)	65.9 (22.6 - 88.8)	59.9 (50.0 - 102.1)	65.9 (50.3 - 102.1)	59.2 (50.0 - 91.8)
IQR	50.5 - 73.0	52.8 - 74.1	42.2 - 71.0	55.1 - 66.3	58.4 - 73.8	54.8 - 65.2
Age group, N (%)						
18 to 29 years	10 (3.82%)	8 (3.76%)	2 (4.08%)	-	-	-
30 to 39 years	24 (9.16%)	17 (7.98%)	7 (14.29%)	-	-	-
40 to 49 years	30 (11.45%)	23 (10.8%)	7 (14.29%)	-	-	-
50 to 59 years	30 (11.45%)	26 (12.21%)	4 (8.16%)	730 (46.17%)	53 (26.11%)	677 (49.13%)
60 to 69 years	65 (24.81%)	52 (24.41%)	13 (26.53%)	570 (36.05%)	71 (34.98%)	499 (36.21%)
70 to 79 years	74 (28.24%)	62 (29.11%)	12 (24.49%)	222 (14.04%)	53 (26.11%)	169 (12.26%)
$\geq$ 80 years	29 (11.07%)	25 (11.74%)	4 (8.16%)	59 (3.73%)	26 (12.81%)	33 (2.39%)
<i>Total available information</i>	262	213	49	1581	203	1378
Gender N (%)						
Female	108 (41.22%)	89 (41.78%)	19 (38.78%)	600 (37.95%)	84 (41.38%)	516 (37.45%)
Male	154 (58.78%)	124 (58.22%)	30 (61.22%)	981 (62.05%)	119 (58.62%)	862 (62.55%)

hATTR-CM: hereditary transthyretin amyloid cardiomyopathy; wtATTR-CM: wild-type transthyretin amyloid cardiomyopathy; IQR: interquartile range; SD: standard deviation

279 **Regarding the distribution of cases by state of residence, considering all patients**  
280 **(n=262) and the hATTR-CM reference cohort (n=213), most patients lived**  
281 **in São Paulo (31.5% and 26.5%, respectively), Minas Gerais (17.7% and**  
282 **19.9%), Bahia (9.6% and 10.4%), Paraná (7.7% and 8.5%), and Rio de**  
283 **Janeiro (6.9% and 7.1%, respectively). For hATTR-CM-like cohort**  
284 **(n=49), higher proportions of patients were observed in São Paulo (53.1%),**  
285 **Distrito Federal (10.2%), Minas Gerais (8.2%), Bahia (6.1%) and Rio de**  
286 **Janeiro (6.1%) (**

287 Table 5).

288 **For wtATTR-CM cohort, considering all patients (n=1,581), most patients lived in São**  
289 **Paulo (40.2%), Minas Gerais (10.8%), Bahia (8.1%), and Pernambuco**  
290 **(7.2%)**Error! Reference source not found.. **The same trend was observed**  
291 **in wtATTR-CM-like group, with most patients living in São Paulo**  
292 **(40.5%), Minas Gerais (10.0%), Bahia (8.43%), and Pernambuco (7.46%).**  
293 **For wtATTR-CM reference cohort (n=203), higher proportions of patients**  
294 **were observed in São Paulo (38.3%), Minas Gerais (15.9%), Bahia (6.0%),**  
295 **and Rio Grande do Sul (6.0%) (**

296 Table 5).

297 **Table 5.** Distribution of ATTR-CM cases, from 2014 to 2021, according to the state of residence

	hATTR-CM			wtATTR-CM		
	Total 262	hATTR-CM reference 213	hATTR-CM-like 49	Total 1581	wtATTR-CM reference 203	wtATTR-CM- like 1378
Acre	0 (0%)	0 (0%)	0 (0%)	1 (0.06%)	1 (0.5%)	0 (0%)
Alagoas	1 (0.38%)	1 (0.47%)	0 (0%)	14 (0.91%)	3 (1.49%)	11 (0.82%)
Amapá	0 (0%)	0 (0%)	0 (0%)	1 (0.06%)	0 (0%)	1 (0.07%)
Amazonas	1 (0.38%)	1 (0.47%)	0 (0%)	6 (0.39%)	2 (1%)	4 (0.3%)
Bahia	25 (9.62%)	22 (10.43%)	3 (6.12%)	125 (8.11%)	12 (5.97%)	113 (8.43%)
Ceará	4 (1.54%)	4 (1.9%)	0 (0%)	42 (2.73%)	4 (1.99%)	38 (2.84%)
Distrito Federal	8 (3.08%)	3 (1.42%)	5 (10.2%)	32 (2.08%)	2 (1%)	30 (2.24%)
Espírito Santo	6 (2.31%)	6 (2.84%)	0 (0%)	30 (1.95%)	2 (1%)	28 (2.09%)
Goiás	16 (6.15%)	14 (6.64%)	2 (4.08%)	32 (2.08%)	11 (5.47%)	21 (1.57%)
Maranhão	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mato Grosso	1 (0.38%)	1 (0.47%)	0 (0%)	7 (0.45%)	0 (0%)	7 (0.52%)
Mato Grosso do Sul	5 (1.92%)	3 (1.42%)	2 (4.08%)	9 (0.58%)	2 (1%)	7 (0.52%)
Minas Gerais	46 (17.69%)	42 (19.91%)	4 (8.16%)	166 (10.77%)	32 (15.92%)	134 (10%)
Pará	1 (0.38%)	1 (0.47%)	0 (0%)	1 (0.06%)	1 (0.5%)	0 (0%)
Paraíba	3 (1.15%)	3 (1.42%)	0 (0%)	14 (0.91%)	1 (0.5%)	13 (0.97%)
Paraná	20 (7.69%)	18 (8.53%)	2 (4.08%)	84 (5.45%)	11 (5.47%)	73 (5.45%)
Pernambuco	4 (1.54%)	3 (1.42%)	1 (2.04%)	111 (7.2%)	11 (5.47%)	100 (7.46%)
Piauí	1 (0.38%)	1 (0.47%)	0 (0%)	5 (0.32%)	1 (0.5%)	4 (0.3%)
Rio de Janeiro	18 (6.92%)	15 (7.11%)	3 (6.12%)	46 (2.99%)	8 (3.98%)	38 (2.84%)
Rio Grande do Norte	3 (1.15%)	3 (1.42%)	0 (0%)	8 (0.52%)	1 (0.5%)	7 (0.52%)
Rio Grande do Sul	5 (1.92%)	5 (2.37%)	0 (0%)	75 (4.87%)	12 (5.97%)	63 (4.7%)
Rondônia	2 (0.77%)	2 (0.95%)	0 (0%)	4 (0.26%)	1 (0.5%)	3 (0.22%)
Roraima	0 (0%)	0 (0%)	0 (0%)	1 (0.06%)	0 (0%)	1 (0.07%)
Santa Catarina	5 (1.92%)	4 (1.9%)	1 (2.04%)	51 (3.31%)	6 (2.99%)	45 (3.36%)
São Paulo	82 (31.54%)	56 (26.54%)	26 (53.06%)	620 (40.23%)	77 (38.31%)	543 (40.52%)
Sergipe	3 (1.15%)	3 (1.42%)	0 (0%)	53 (3.44%)	0 (0%)	53 (3.96%)
Tocantins	0 (0%)	0 (0%)	0 (0%)	3 (0.19%)	0 (0%)	3 (0.22%)
Unknown	2	2	0	40	2	38

298 hATTR-CM: hereditary transthyretin amyloid cardiomyopathy; wtATTR-CM: wild-type transthyretin amyloid cardiomyopathy.

299 ***Proportion of ICD-10 codes most presented as ATTR-CM-like cases in DATASUS***

300 The ICD-10 codes most presented as hATTR-CM in the overall cohort (n=262) were I50.0  
301 Congestive Heart Failure (59.5%), I50.9 Heart Failure, unspecified (41.9%), N18.9 chronic  
302 kidney disease, unspecified (27.5%), I44.2 Total atrioventricular block (18.3%), and I48.0  
303 Flutter and atrial fibrillation (16.4%) (Fig 2). Considering only the hATTR-CM reference  
304 cohort (n=213), most prevalent ICD-10 codes were I50.0 Congestive Heart Failure (73.2%),  
305 I50.9 Heart Failure, unspecified (51.6%), N18.9 chronic kidney disease, unspecified (30.5%),  
306 I44.2 Total atrioventricular block (22.5%), and I48.0 Flutter and atrial fibrillation (19.3%).  
307 For hATTR-CM-like cohort, on the other side, most common cardiac-related ICD-10 codes  
308 were N18.9 chronic kidney disease, unspecified (18.4%), N18.8 Other chronic kidney disease  
309 (12.2%), I47.2 Ventricular tachycardia (8.2%), and G56.0 Carpal tunnel syndrome (6.1%)  
310 (Fig 2).

311 **Fig 2.** Cardiac-related ICD-10 codes most frequent in hATTR-CM patients

312 For the wtATTR-CM cohort, heart failure and arrhythmias were the ICD-10 codes most  
313 presented in the overall cohort (n=1,581), with I50.0 Congestive Heart Failure (78.7%), I50.9  
314 Heart Failure, unspecified (54.5%), I44.2 Total atrioventricular block (19.4%), I42.0 Dilated  
315 cardiomyopathy (18.4%), and N18.9 chronic kidney disease, unspecified (17.7%) (Fig 3).  
316 Considering only the wtATTR-CM reference cohort (n=203), most prevalent ICD-10 codes  
317 were I50.0 Congestive Heart Failure (63.1%), I50.9 Heart Failure, unspecified (59.6%), I44.2  
318 Total atrioventricular block (26.6%), and N18.9 chronic kidney disease, unspecified  
319 (26.6%%). For wtATTR-CM-like cohort (n=1,378) most common cardiac-related ICD-10  
320 codes were I50.0 Congestive heart failure (81.0%), I50.9 Heart failure, unspecified (53.8%),

321 I42.0 Dilated cardiomyopathy (19.7%), I44.2 Total atrioventricular block (18.4%), and  
322 N18.9 chronic kidney disease, unspecified (16.3%) (Fig 3).

323 **Fig 3.** Cardiac-related ICD-10 codes most frequent in wtATTR-CM patients

324 *Annual ATTR-CM hospitalization rate*

325 Higher hospitalization rates were observed in the hATTR-CM reference compared to  
326 hATTR-CM-like group. The years with the higher hospitalization rates were 2017 and 2018,  
327 for hATTR-CM reference, and 2017, 2019 and 2020 for hATTR-CM-like cohort (Fig 4).

328 **Fig 4.** Annual hATTR-CM hospitalization rate from 2015 to 2021

329 The opposite was observed for wtATTR-CM-like patients, which had a higher rate of  
330 hospitalization throughout the study period compared to wtATTR-CM reference patients.  
331 The years with the higher hospitalization rates were 2017 and 2018, for the wtATTR-CM  
332 reference, and 2015 and 2018 for wtATTR-CM-like cohort (Fig 5).

333 **Fig 5.** Annual wtATTR-CM hospitalization rate from 2015 to 2021

334 *ATTR-CM therapeutic itinerary and healthcare resource utilization within SUS*

335 *Inpatient setting*

336 **Overall, hospitalizations were more frequent among hATTR-CM reference patients**  
337 **compared to hATTR-CM-like. For the entire cohort (n=262), 217 (82.8%)**  
338 **patients had at least one record of hospitalization. The proportion of**  
339 **hospitalized patients decreased comparing hATTR-CM reference (94.4%)**  
340 **to hATTR-CM-like (32.7%). Median hospitalization rate per patient was**  
341 **4.0 (IQR 2.0-8.0) for all patients, with similar trend in hATTR-CM**  
342 **reference (median [IQR 2.0-9.0]) and decreased in hATTR-CM-like**  
343 **(median 1.0 [IQR 1.0-2.2]). Median hospitalization rate per patient per**  
344 **year (PPPY) was 1.5 (IQR 1.0-2.2) for all patients. However, analysis by**

345 **type of hATTR-CM revealed that hATTR-CM-like had a PPPY**  
346 **hospitalization rate 50% higher than hATTR-CM reference (1.50 [IQR**  
347 **1.0-2.2] and 1.0 [1.0-1.6], respectively). The median number of days in**  
348 **hospital per patient (total days of hospitalization during follow up) was 6.0**  
349 **(IQR 3.0-12.0) for all patients, with a decreasing trend comparing hATTR-**  
350 **CM reference (6.0 days [IQR 3.0-12.0]) to hATTR-CM-like (4.0 days [IQR**  
351 **1.0-10.5] (**



352 Table 6).

353 *Outpatient setting*

354 **In the outpatient setting, hATTR-CM-like patients had more outpatient visits**  
355 **compared to hATTR-CM reference. For the entire cohort (n=262), 244**  
356 **(93.1%) patients had at least one record of outpatient visit related to the**  
357 **hATTR. The proportion of patients with record of outpatient visits was**  
358 **higher in hATTR-CM-like (98.0%) compared to hATTR-CM reference**  
359 **(92.0%). Median number of outpatient visits per patient was 8.0 (IQR 2.8-**  
360 **20) for all patients. Median number of outpatient visits PPPY was 5.0 (IQR**  
361 **2.0-8.0) for all patients. However, analysis by disease type revealed that**  
362 **hATTR-CM reference had less outpatient visits PPPY compared to**  
363 **hATTR-CM-like (5.0 [IQR 2.0-7.5] and 6.3 [IQR 1.0-8.7], respectively) (**

364 Table 6).

365 *Therapeutic Itinerary*

366 **For the entire cohort (n=262), 35 (13.4%) patients had at least one claim for tafamidis**  
367 **meglumine, of which 31 (14,6%) were in the hATTR-CM reference group,**  
368 **and 4 (8.2%) were in the hATTR-CM-like group. There was no record of**  
369 **heart or liver transplant in the hATTR-CM cohort. The median number of**  
370 **treatment claims per hATTR-CM patient during the study period was 3.0**  
371 **(IQR 1.5-11), varying from 3.0 (IQR 1.5-11) in the hATTR-CM reference**  
372 **cohort to 5.5 (IQR 1.8-9.8) in the hATTR-CM-like cohort. Median number**  
373 **of treatment claims PPPY was 2.0 (IQR 1.5-5.5) for all patients and for**  
374 **hATTR-CM reference cohort. The hATTR-CM-like group had a median**  
375 **number of treatment claims PPPY of 4.0 (IQR1.8-6.8) (**

376 Table 6).

377 *Procedure metrics*

378 **The patterns of procedures claims were identical across disease types and for the**  
379 **entire cohort. Median number of procedures claims during the study**  
380 **period was 1.0 (IQR 1.0-1.0) and median PPPY was 1.0 (IQR 1.0-1.0). It**  
381 **was considered only claims of procedures defined for this study and**  
382 **related to the selected study ICD-10 codes (**

383 Table 6).

384 *Wild type ATTR-CM*

385 *Inpatient setting*

386 **Overall, hospitalizations were similar across wtATTR-CM reference and wtATTR-**  
387 **CM-like patients. For the entire cohort (n=1,581), 1,532 (96.9%) patients**  
388 **had at least one record of hospitalization. The proportion of hospitalized**  
389 **patients was very similar between wtATTR-CM reference (96.6%) and**  
390 **wtATTR-CM-like (96.9%). Median hospitalization rate per patient was 4.0**  
391 **(IQR 2.0-8.0) for all patients, with similar trend in wtATTR-CM reference**  
392 **and wtATTR-CM-like. Median hospitalization rate PPPY was 1.8 (IQR**  
393 **1.0-2.5) for all patients. Analysis by type of wtATTR-CM revealed that**  
394 **wtATTR-CM-like and wtATTR-CM refence had a PPPY hospitalization**  
395 **rate almost identical (1.70 [IQR 1.0-2.2] and 1.8 [1.0-2.5], respectively).**  
396 **The median number of days in hospital per patient (total days of**  
397 **hospitalization during follow up) was 6.0 (IQR 3.0-12.0) for all patients, 5.0**  
398 **(IQR 2.0-10.0) for wtATTR-CM reference and 7.0 (IQR 3.0-14.0) for**  
399 **wtATTR-CM-like (**

400 Table 6).

401 *Outpatient setting*

402 **In the outpatient setting, outpatient visits seem similar across disease types. For the**  
403 **entire cohort (n=1,581), 1,344 (85.0%) patients had at least one record of**  
404 **outpatient visit related to the wtATTR-CM. The proportion of patients**  
405 **with record of outpatient visits was higher in wtATTR-CM reference**  
406 **(87.2%) compared to wtATTR-CM-like (84.7%). Overall, the median**  
407 **number of outpatient visits per patient was 2.0 (IQR 1.0-4.0) for all**  
408 **patients. Median number of outpatient visits PPPY was 1.0 (IQR 1.0-2.0)**  
409 **for all patients and across disease types (**

410 Table 6).

411 *Therapeutic itinerary*

412 **For the entire cohort (n=1,518), 80 (5.1%) patients had at least one claim for tafamidis**  
413 **meglumine, of which 6 (3.0%) were in the wtATTR-CM reference group,**  
414 **and 74 (5.4%) were in the wtATTR-CM-like group. Overall, 28.9% of the**  
415 **wtATTR-CM cohort had record of heart transplant. Analysis by disease**  
416 **type revealed that from these, 1 (0.5%) was in the wtATTR-CM reference**  
417 **group and 456 (33.1%) were in the wtATTR-CM-like group. The median**  
418 **number of ATTR-CM-related treatment claims during the study period**  
419 **was 3.0 (IQR 2.0-6.0) for the entire cohort, with similar trends between**  
420 **wtATTR-CM reference and wtATTR-CM-like. Median number of**  
421 **treatment claims PPPY was 1.5 (IQR 1.0-2.1) for all patients, varying from**  
422 **1.4 (IQR 1.0-2.0) in the wtATTR-CM reference cohort to 1.7 (IQR 1.0-2.2)**  
423 **in the hATTR-CM-like group (**

424 Table 6).

425 *Procedure metrics*

426 **The patterns of procedures claims were very similar across disease types and for the**  
427 **entire cohort. Median number of procedures claims during the study**  
428 **period was 1.0 (IQR 1.0-2.0) and median PPPY was 1.0 (IQR 1.0-1.0).**  
429 **Were considered only claims of procedures defined for this study and**  
430 **related to the selected study ICD-10 codes (**

431 Table 6).



**Table 6.** Treatment patterns and healthcare resources utilization of ATTR-CM patients, from 2015 to 2021, per ATTR-CM type

	hATTR-CM			wtATTR-CM		
	Total	hATTR-CM reference	hATTR-CM- like	Total	wtATTR-CM reference	wtATTR-CM- like
	262	213	49	1581	203	1378
<b><i>Inpatient setting<sup>1</sup></i></b>						
Hospital admissions (n)	1711	1677	34	11724	1532	10192
Mean (SD) per patient	7.9 (15.3)	8.3 (15.8)	2.1 (1.9)	7.7 (13.5)	7.8 (13.6)	7.6 (13.5)
Median (IQR) per patient	4 (2 - 8)	4 (2 - 9.0)	1 (1 - 2.2)	4 (2 - 8)	4 (2 - 7)	4 (2 - 8)
Median (IQR) PPPY	1.5 (1.0 - 2.2)	1.5 (1.0 - 2.2)	1.0 (1.0 - 1.6)	1.8 (1.0 - 2.5)	1.7 (1.0 - 2.2)	1.8 (1.0 - 2.5)
Patients with at least one admission, n (%)	217 (82.82%)	201 (94.37%)	16 (32.65%)	1532 (96.9%)	196 (96.55%)	1336 (96.95%)
Total length of stay, days						
Mean (SD)	9.5 (11.4)	9.5 (11.3)	9.9 (16.2)	10.5 (13.3)	8.5 (10.8)	10.7 (13.6)
Median (IQR)	6.0 (3.0 - 12.0)	6.0 (3.0 - 12.0)	4.0 (1.0 - 10.5)	6.0 (3.0 - 13.0)	5.0 (2.0 - 10.0)	7.0 (3.0 - 14.0)
<b><i>Outpatient setting<sup>1</sup></i></b>						
Outpatient visits (n)	2752	2128	624	6321	886	5435
Mean (SD) per patient	11.3 (10.3)	10.9 (10.1)	13.0 (10.9)	4.7 (12.1)	5.0 (8.8)	4.7 (12.5)
Median (IQR) per patient	8 (2.8 - 20)	7 (3 - 17.5)	14 (2 - 24.2)	2 (1 - 4)	2 (1 - 4)	2 (1 - 4)
Median (IQR) PPPY	5.0 (2.0 - 8.0)	5.0 (2.0 - 7.5)	6.3 (1.0 - 8.7)	1.0 (1.0 - 2.0)	1.0 (1.0 - 2.0)	1.0 (1.0 - 2.0)
Patients with at least one outpatient visit, n (%)	259	196	63	1344	177	1167
<b><i>Treatment metrics</i></b>						
Treatment claims <sup>2</sup>						
Mean (SD) per patient	5.5 (4.6)	5.5 (4.6)	6.0 (5.4)	6.4 (10.9)	5.3 (7.4)	6.5 (11.2)
Median (IQR) per patient	3 (1.5 - 11)	3.0 (1.5 - 11.0)	5.5 (1.8 - 9.8)	3 (2 - 6)	3 (1 - 6)	3 (2 - 6)
Median (IQR) PPPY	2.0 (1.2 - 5.5)	2.0 (1.2 - 5.5)	4.0 (1.8 - 6.8)	1.5 (1.0 - 2.1)	1.4 (1.0 - 2.0)	1.7 (1.0 - 2.2)
Patients with at least one claim for tafamidis, n (%)	35 (13.36%)	31 (14.55%)	4 (8.16%)	80 (5.06%)	6 (2.96%)	74 (5.37%)

Patients with at least one claim for heart transplant, n (%)	0 (0%)	0 (0%)	0 (0%)	457 (28.91%)	1 (0.49%)	456 (33.09%)
Patients with at least one claim for liver transplant, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Patients with claim for both heart and liver transplant, n (%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)
<b><i>Procedure's metrics</i></b>						
Procedures claims <sup>3</sup>						
Mean (SD) per patient	1 (0.0)	1 (0.0)	1 (0.0)	2.0 (1.9)	1.9 (1.9)	2.0 (2.0)
Median (IQR) per patient	1 (1 - 1)	1 (1 - 1)	1 (1 - 1)	1 (1 - 2)	1 (1 - 2)	1 (1 - 2)
Median (IQR) PPPY	1 (1 - 1)	1 (1 - 1)	1 (1 - 1)	1.0 (1.0 - 1.0)	1.0 (1.0 - 1.0)	1.0 (1.0 - 1.0)

hATTR-CM: hereditary transthyretin amyloid cardiomyopathy; wtATTR-CM: wild-type transthyretin amyloid cardiomyopathy; IQR: interquartile range; PPPY: per patient per year; SD: standard deviation.

<sup>1</sup> Only inpatient or outpatient claims with the ICD-10 codes selected for the study (ATTR-CM-related or cardiac-related).

<sup>2</sup> Any treatment claim with the ICD-10 codes selected for the study (claims restricted to the selected ICD-10 codes). Treatment claims to be considered are: 06.04.54.006-0 tafamidis 20 mg, 05.05.02.004-1 Heart transplant, 05.05.02.005-0 Liver transplant (deceased donor), 05.05.02.006-8 Liver transplant (alive donor), 03.03.06.003-4 Treatment of hypertrophic heart disease, 03.03.06.023-9 Treatment of myocardiopathies, 03.03.06.002-6 Treatment of arrhythmias, 03.03.06.021-2 Heart failure treatment

<sup>3</sup> Any procedure claim with the ICD-10 codes selected for the study (claims restricted to the selected ICD-10 codes). Procedures claims to be considered are: 02.01.01.014-3 Heart biopsy, 02.08.05.002-7 Bone scintigraphy (full body), 02.08.05.001-9 Scintigraphy of joints and/or extremities and/or bone, 02.08.05.003-5 Bone scintigraphy with or without blood flow (full body), 02.07.02.001-9 Heart/aorta magnetic resonance, 04.03.02.012-3 Surgical treatment of carpal tunnel syndrome, 04.08.02.030-0 Tenosynovectomy in upper limb, 02.11.02.003-6 Electrocardiogram, 02.05.01.003-2 Transthoracic echocardiography, 02.05.01.002-4 Transesophageal echocardiography, 02.01.01.037-2 Skin and soft parts biopsy, 02.02.03.120-9 Troponin dosage, 02.02.03.128-4 Dosage BNP and NT-proBNP, 04.06.01.061-7 Endocavitary cardiac pacemaker implant, 04.06.01.062-5 Epimyocardial heart pacer implant, 04.06.01.063-3 Transvenous heart pacemaker implant, 04.06.01.064-1 Epimyocardial dual chamber pacemaker implant, 04.06.01.065-0 Transvenous dual chamber pacemaker implant, 04.06.01.066-8 Epimyocardial single chamber pacemaker implant, 04.06.01.067-6 Transvenous single chamber pacemaker implant, 04.06.01.069-2 Valve prosthesis implant

434 ***ATTR-CM-related procedures***

435 Overall, most performed procedures in the hATTR-CM cohort were tafamidis meglumine  
436 (13.4%), specialized medical visits (5.0%), transthoracic echocardiogram (4.6%), and pre-  
437 transplant procedures (3.8%). For hATTR-CM reference cohort, most performed procedures  
438 were tafamidis meglumine (14.6%), pre-transplant procedures (4.2%), and transthoracic  
439 echocardiogram (3.8%). Considering specifically the hATTR-CM-like group, most  
440 performed procedures were specialized medical visits (14.3%), transthoracic echocardiogram  
441 (8.2%), magnetic resonance of the heart (6.1%), cardiac catheterization (6.1%), and  
442 gabapentin (4.1%) (Fig 6 and Supplementary **Error! Reference source not found.3**).

443 **Fig 6.** Most frequent procedures in hATTR-CM reference and hATTR-CM-like cohorts from  
444 2015 to 2021

445 In the wtATTR-CM cohort, the most performed procedures were tafamidis meglumine  
446 (13.4%), specialized medical visits (5.0%), transthoracic echocardiogram (4.6%), and pre-  
447 transplant procedures (3.8%). For hATTR-CM reference cohort, most performed procedures  
448 were tafamidis meglumine (14.6%), pre-transplant procedures (4.2%), and transthoracic  
449 echocardiogram (3.8%). Considering specifically the hATTR-CM-like group, most  
450 performed procedures were specialized medical visits (14.3%), transthoracic echocardiogram  
451 (8.2%), magnetic resonance of the heart (6.1%), cardiac catheterization (6.1%), and  
452 gabapentin (4.1%) (Fig 7 and Supplementary Table 4).

453 **Fig 7.** Most frequent procedures in wtATTR-CM reference and wtATTR-CM-like cohorts  
454 from 2015 to 2021

## 455 **DISCUSSION**

456 This study used a validated ML model to identify potential ATTR-CM cases in Brazilian  
457 National Health System (SUS). The results allowed to characterize demographically the  
458 ATTR-CM patients and to assess the proportion of ATTR-CM-reference and ATTR-CM-  
459 like cases among potential ATTR-CM cases. In addition, the study results showed the ICD-  
460 10 codes most presented as ATTR-CM-like cases in DATASUS, the annual hospitalization  
461 rate, the treatment patterns of ATTR-CM and ATTR-CM-like cases under SUS treatment  
462 and, finally, the average HCRU of ATTR-CM-reference and ATTR-CM-like cases. To the  
463 best of our knowledge, this is the first time that a ML model is used to assess potential ATTR-  
464 CM cases in the Brazilian national health system.

465 Overall, our final validated ML model had a good performance for classifying ATTR-CM  
466 cases from a retrospective analysis approach, in line with other predictive studies using ML  
467 models (10,14,18). The accuracy was 78.06% for wtATTR-CM and 84.4% for hATTR-CM.  
468 We identified possible under-recognized ATTR-CM cases from the data available in  
469 DATASUS. According to the final classification of the ML model, 10.3% of hATTR-CM  
470 patients and 21.6% of wtATTR-CM patients (potential ATTR-CM cases) may have been  
471 under-recognized between 2015 and 2021. The delay in the diagnoses and the misdiagnoses  
472 of ATTR is often reported in literature (18,23,24). The reasons for diagnostic delay are  
473 multifactorial and include symptom overlap with other conditions, low disease awareness,  
474 the historical need for invasive diagnosis, and until recently the lack of a disease-modifying  
475 treatment (23). A previous study also identified under-recognized ATTR-CM cases in 4  
476 different databases from USA, using ML model (18). The authors highlighted the importance

477 of ML model as a tool to help in the early diagnostic, resulting in a good prognostic of the  
478 disease (18).

479 A smaller proportion of under-recognized cases was identified in the hATTR-CM cohort  
480 compared to wtATTR-CM, probably because this cohort was built over a more restrict  
481 population, that is, patients with hereditary amyloidosis ICD-10 codes. On the other hand, in  
482 the wtATTR-CM cohort there was a higher proportion of underdiagnosed patients. While  
483 only 203 patients were classified as reference by the ML model, 1,581 patients were  
484 classified as wtATTR-CM-like cases, which may be indicative of a higher prevalence of the  
485 disease among older adults than expected. Previous studies have demonstrated that the  
486 clinical overlap between wtATTR-CM and other heart failure aetiologies is high (18,23,25),  
487 what can explain our finding.

488 Diagnosing ATTR-CM can be difficult, mainly for the wild-type, as cardiac symptoms are  
489 consistent with more common types of heart failure and the extra-cardiac manifestations are  
490 heterogeneous and nonspecific (23). In one study developed in Spain, 30% of the patients  
491 with ATTR-CM had previously been misdiagnosed with other cardiac diseases such as:  
492 hypertensive heart disease, hypertrophic cardiomyopathy and ischemic heart disease (25). In  
493 our study, the ICD-10 codes most related with ATTR-CM presented a similar profile to these  
494 findings.

495 Some patients with hATTR-CM may have a mixed phenotype, with cardiac and neurological  
496 manifestations. In our study, the prevalence of cardiac manifestations among hATTR patients  
497 was 24.8%, which is in line with the literature (26). Previous studies have demonstrated that  
498 in patients with mixed phenotype the diagnostic delay is shorter than in patients with only  
499 cardiac manifestations (23,27). The early diagnosis can result in a better disease prognosis

500 and in an adequate treatment, since a disease-modifying treatment is available for ATTR-  
501 CM treatment in Brazil.

502 Regarding the geographic distribution of the patients, a higher concentration was observed  
503 in the South and Southeast regions in this study, probably because these are the Brazilian  
504 regions with the higher number of specialized hospitals and clinics (28,29). Access to medical  
505 care in Brazil is widely influenced by the concentration of services in large urban centres  
506 (30). The territorial extension of Brazil makes it even more important and challenging to  
507 provide a highly coordinated multi-layered healthcare system (30). Therefore, it was  
508 expected a higher proportion of patients referred to more developed regions.

509 Concerning the therapeutic itinerary, tafamidis meglumine is the only specific drug treatment  
510 available in SUS for ATTR-CM treatment. In addition to tafamidis meglumine, heart  
511 transplantation is also available, however, due to its invasive characteristic it is considered  
512 only in extreme cases (15). For the hATTR-CM patients, 13% received treatment with  
513 tafamidis meglumine and there was no record of heart transplant, while for wtATTR-CM  
514 patients only 5% were treated with tafamidis meglumine and 29% were referred to a heart  
515 transplantation. This data call attention, one more time, for the importance of an early  
516 diagnosis in the disease progression. wtATTR-CM patients, once early diagnosed, could have  
517 received the drug treatment, avoiding the heart transplantation (19,24). It is important to note  
518 that for hATTR-CM patients, although they were expected to have heart and liver  
519 transplantation (31,32), it was not identified in the study period. However, procedures related  
520 to the management of post-transplant patient and the use of tacrolimus, a drug used to prevent  
521 transplant organ rejection, appeared among the most common procedures i.e., these patients  
522 may have had transplantation before 2015 and were performing the maintenance during the  
523 study period. Another consideration refers to low number of heart and liver transplant in the

524 study period and the introduction of tafamidis meglumine in SUS in 2016, which could be  
525 related, as previously demonstrated in a 20-year retrospective study of the Familial  
526 Amyloidosis Polyneuropathy World Transplant Registry (31).

527 The hospitalization rate and the resource utilization also evidence unmet medical needs,  
528 especially for wild-type patients; although a formal comparison was not performed, the  
529 hospitalization rate was much higher in the ATTR-CM-like group than in the ATTR-CM-  
530 reference group. These patients may have more hospitalizations records because lack of  
531 correct diagnosis and, consequently, lack of proper disease management. A previous study  
532 demonstrated that the use tafamidis meglumine was associated with a lower rate of  
533 hospitalization as well as a shorter length of stay per hospitalization among all treated  
534 patients, mainly when the treatment was initiated in patients at early disease stage (33).

535 Moreover, reductions in hospitalization rates might occur due to several factors (34). In 2020  
536 and 2021, however, these factors were compounded by the effect of the pandemic caused by  
537 the novel coronavirus (34). In Brazil, the entire healthcare system was impacted, not only by  
538 the demand for care of COVID-19 cases, but also by the isolation and social distancing  
539 measures that compromised people's access to healthcare services (34). In this study, we  
540 identified a reduction in hospitalization rates for both wtATTR-CM and hATTR-CM cohorts,  
541 probably related to the isolation and social distancing arising from COVID-19 pandemic.

542 The major limitation of retrospective data is that the data are often incomplete, and this study  
543 depended on the quality and filling of non-mandatory data, which is intrinsic to retrospective  
544 database studies (35). Also, due to the administrative characteristics of the databases that  
545 were used, few clinical information was available, therefore the only specific predictive  
546 variables for identifying ATTR-CM-related cases in the model were ICD-10 code and

547 procedures performed. Another important limitation is that DATASUS uses the International  
548 Classification of Diseases (10<sup>th</sup> version), which does not have a code for ATTR-CM, so we  
549 conducted the study based on the assumption of using a set of parameters validated by experts  
550 and key opinion leaders (including ICD-10 code and clinical procedures performed) for  
551 predicting ATTR-CM cases.

552 To reduce the probability of including patients with diseases different from ATTR-CM, we  
553 have defined very specific mandatory procedures for classifying ATTR-CM and ATTR-CM-  
554 like cases. This might have an impact in the number of patients identified by the model for a  
555 few reasons.

556 Firstly, these are more expensive and specialized procedures. In the context of the Brazilian  
557 public health system, it is expected that there are barriers to access these type of procedures  
558 (36). Therefore, it is supposed that there is a lower number of patients undergoing these  
559 procedures, which might have been reflected in the model results.

560 Secondly, we believe that the suspicion of amyloidosis in patients with heart failure is likely  
561 to be restricted to large centres (e.g., teaching hospitals, specialized clinics), as many  
562 physicians may not be familiar with ATTR-CM management (1), which can result in fewer  
563 patients who underwent diagnostic confirmation procedures.

564 Blind spots in machine learning can reflect the worst societal biases, with a risk of unintended  
565 or unknown accuracies in minority subgroups, and there are concerns over the potential for  
566 amplifying biases present in the data collected, which might lead to discriminatory bias (37).

## 567 **CONCLUSION**

568 The outcomes found in this study supported the identification of potential ATTR-CM cases  
569 in DATASUS using a validated ML model, reflecting the public health system in Brazil. We



570 were able to characterize this population demographically, clinically (considering their ICD-  
571 10 codes and procedures performed), and to identify the HCRU related to ATTR-CM  
572 management. Our findings may be useful to support the development of health guidelines  
573 and policies to improve diagnosis, treatment and to cover unmet medical needs of patients  
574 with ATTR-CM in Brazil.

575 **Acknowledgements:** The authors also thank Lucas Sozzi de Jesus and Lays Leonel for their  
576 medical writing support, and Ramon Pereira in the revision of the analysis.

577 **Declaration of interests:** IZL, RVF and AJLA are full-time employees at IQVIA Brazil.  
578 CCH, CLBS and GSJ are full-time employees at Pfizer Brazil.

579 **Funding:** This study was funded by Pfizer Brazil.

580 **Financial disclosure:** The author(s) received no specific funding for this work.

581 **REFERENCES**


- 582 1. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid  
583 Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol* [Internet]. 2019  
584 Jun;73(22):2872–91. Available from:  
585 <https://linkinghub.elsevier.com/retrieve/pii/S0735109719347291>
- 586 2. Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al.  
587 Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients  
588 with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur*  
589 *Heart J*. 2017;38(38):2879–87.
- 590 3. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al.  
591 Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel  
592 Release. *J Am Coll Cardiol*. 2018;72(17):2040–50.
- 593 4. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et  
594 al. Left ventricular amyloid deposition in patients with heart failure and preserved  
595 ejection fraction. *JACC Hear Fail*. 2014;2(2):113–22.
- 596 5. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al.  
597 Natural History, Quality of Life, and Outcome in Cardiac Transthyretin  
598 Amyloidosis. *Circulation*. 2019 Jul;140(1):16–26.
- 599 6. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al.  
600 Prospective evaluation of the morbidity and mortality of wild-type and V122I  
601 mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis  
602 Cardiac Study (TRACS). *Am Heart J*. 2012 Aug;164(2):222-228.e1.
- 603 7. Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, et  
604 al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single  
605 UK center experience. *Hum Mutat*. 2019 Jan;40(1):90–6.
- 606 8. Kittleson MM, Maurer MS, Ambardekar A V, Bullock-Palmer RP, Chang PP, Eisen  
607 HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific  
608 Statement From the American Heart Association. *Circulation*. 2020 Jul;142(1):e7–  
609 22.

- 610 9. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening  
611 for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. *JACC Hear Fail*  
612 [Internet]. 2019 Aug;7(8):709–16. Available from:  
613 <https://linkinghub.elsevier.com/retrieve/pii/S2213177919302720>
- 614 10. Ellis RJ, Wang Z, Genes N, Ma’ayan A. Predicting opioid dependence from  
615 electronic health records with machine learning. *BioData Min* [Internet]. 2019 Dec  
616 29;12(1):3. Available from:  
617 <https://biodatamining.biomedcentral.com/articles/10.1186/s13040-019-0193-0>
- 618 11. Deodhar A, Rozycki M, Garges C, Shukla O, Arndt T, Grabowsky T, et al. Use of  
619 machine learning techniques in the development and refinement of a predictive  
620 model for early diagnosis of ankylosing spondylitis. *Clin Rheumatol* [Internet]. 2020  
621 Apr 1;39(4):975–82. Available from: [http://link.springer.com/10.1007/s10067-019-](http://link.springer.com/10.1007/s10067-019-04553-x)  
622 [04553-x](http://link.springer.com/10.1007/s10067-019-04553-x)
- 623 12. An S, Malhotra K, Dilley C, Han-Burgess E, Valdez JN, Robertson J, et al.  
624 Predicting drug-resistant epilepsy — A machine learning approach based on  
625 administrative claims data. *Epilepsy Behav* [Internet]. 2018 Dec;89:118–25.  
626 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1525505018305912>
- 627 13. Uspenskaya-Cadoz O, Alamuri C, Wang L, Yang M, Khinda S, Nigmatullina Y, et  
628 al. MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED  
629 PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL  
630 POPULATION. *J Prev Alzheimer’s Dis* [Internet]. 2019;1–7. Available from:  
631 <https://link.springer.com/article/10.14283/jpad.2019.10>
- 632 14. Nori VS, Hane CA, Martin DC, Kravetz AD, Sanghavi DM. Identifying incident  
633 dementia by applying machine learning to a very large administrative claims dataset.  
634 Chen K, editor. *PLoS One* [Internet]. 2019 Jul 5;14(7):e0203246. Available from:  
635 <https://dx.plos.org/10.1371/journal.pone.0203246>
- 636 15. Brasil. Ministério da Saúde. DATASUS. Informatics Department of SUS. [Internet].  
637 2022. Available from: <https://datasus.saude.gov.br/>
- 638 16. IBGE. Comitê de Estatísticas Sociais. Sistema de Informações Hospitalares do SUS

- 639 – SIH/SUS. [Internet]. 2022. Available from: [https://ces.ibge.gov.br/base-de-](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-hospitalares-do-sus-sih-sus.html)  
640 [dados/metadados/ministerio-da-saude/sistema-de-informacoes-hospitalares-do-sus-](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-hospitalares-do-sus-sih-sus.html)  
641 [sih-sus.html](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-hospitalares-do-sus-sih-sus.html)
- 642 17. IBGE. Comitê de Estatísticas Sociais. Sistema de Informações Ambulatoriais do  
643 SUS – SIA/SUS [Internet]. 2022. Available from: [https://ces.ibge.gov.br/base-de-](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-ambulatoriais-do-sus-sia-sus.html)  
644 [dados/metadados/ministerio-da-saude/sistema-de-informacoes-ambulatoriais-do-sus-](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-ambulatoriais-do-sus-sia-sus.html)  
645 [sia-sus.html](https://ces.ibge.gov.br/base-de-dados/metadados/ministerio-da-saude/sistema-de-informacoes-ambulatoriais-do-sus-sia-sus.html)
- 646 18. Huda A, Castaño A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine  
647 learning model for identifying patients at risk for wild-type transthyretin amyloid  
648 cardiomyopathy. *Nat Commun* [Internet]. 2021 Dec 11;12(1):2725. Available from:  
649 <http://www.nature.com/articles/s41467-021-22876-9>
- 650 19. Simões M V., Fernandes F, Marcondes-Braga FG, Scheinberg P, Correia E de B,  
651 Rohde LEP, et al. Posicionamento sobre Diagnóstico e Tratamento da Amiloidose  
652 Cardíaca – 2021. *Arq Bras Cardiol*. 2021;117(3):561–98.
- 653 20. Brasil. Ministério da Saúde. Portaria GM/MS nº 2.848, de 06 de novembro de 2007.  
654 Publica a Tabela de Procedimentos, Medicamentos, Órteses, Próteses e Materiais  
655 Especiais - OPM do Sistema Único de Saúde. 2007.
- 656 21. Brasil. Conselho Nacional de Saúde. Resolução nº 510, de 07 de Abril de 2016.  
657 Brasília. Brasil. 2016.
- 658 22. Campos D, Rosim R, Duva A, Ballalai A. Brazilian Healthcare Record Linkage  
659 (BRHC-RLK)-A Record Linkage Methodology For Brazilian Medical Claims  
660 Datasets (DATASUS). *Value Heal*. 2017;20(5):A321.
- 661 23. Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et  
662 al. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin  
663 Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. *Cardiol*  
664 *Ther*. 2021 Jun;10(1):141–59.
- 665 24. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis  
666 and treatment of cardiac amyloidosis: a position statement of the ESC Working  
667 Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2021 Apr;42(16):1554–

- 668 68.
- 669 25. González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of  
670 Transthyretin Cardiac Amyloidosis. Progress and Hope. Rev Española Cardiol  
671 (English Ed.
- 672 26. Cruz MW, Pinto MV, Pinto LF, Gervais R, Dias M, Perez C, et al. Baseline disease  
673 characteristics in brazilian patients enrolled in transthyretin amyloidosis outcome  
674 survey (THAOS). Arq Neuropsiquiatr. 2019;77(2):96–100.
- 675 27. Bishop E, Brown EE, Fajardo J, Barouch LA, Judge DP, Halushka MK. Seven  
676 factors predict a delayed diagnosis of cardiac amyloidosis.  
677 <https://doi.org/101080/1350612920181498782>. 2018 Jul;25(3):174–9.
- 678 28. da Mota Almeida Peroni F, Lindelow M, Oliveira De Souza D, Sjoblom M.  
679 Realizing the right to health in Brazil’s Unified Health System through the lens of  
680 breast and cervical cancer. Int J Equity Health [Internet]. 2019 Dec 3;18(1):39.  
681 Available from: [https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-](https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-019-0938-x)  
682 [019-0938-x](https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-019-0938-x)
- 683 29. Pan American Health Organization/World Health Organization (PAHO/WHO).  
684 Brazil Health System and Services Profile. Monitoring and Analysis of Health  
685 Systems Change/Reform. 2009.
- 686 30. Fonseca B de P, Albuquerque PC, Saldanha R de F, Zicker F. Geographic  
687 accessibility to cancer treatment in Brazil: A network analysis. Lancet Reg Heal -  
688 Am [Internet]. 2022 Mar;7:100153. Available from:  
689 <https://linkinghub.elsevier.com/retrieve/pii/S2667193X21001496>
- 690 31. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al.  
691 Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still  
692 the Best Therapeutic Alternative? Transplantation. 2015 Sep;99(9):1847–54.
- 693 32. Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies S.  
694 Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil.  
695 Liver Transplant. 2002;8(1):34–9.
- 696 33. Rozenbaum MH, Tran D, Bhambri R, Nativi-Nicolau J, Edu NJ. Annual

- 697 Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients  
698 with Transthyretin Amyloid Cardiomyopathy. *Am J Cardiovasc Drugs* 2022 224.  
699 2022 Mar;22(4):445–50.
- 700 34. Guimarães RA, Policena GM, Paula H da SC de, Pedroso CF, Pinheiro RS, Itria A,  
701 et al. Analysis of the impact of coronavirus disease 19 on hospitalization rates for  
702 chronic non-communicable diseases in Brazil. Schwartzman K, editor. *PLoS One*  
703 [Internet]. 2022 Mar 24;17(3):e0265458. Available from:  
704 <https://dx.plos.org/10.1371/journal.pone.0265458>
- 705 35. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A  
706 Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on  
707 Retrospective Databases. *Value Heal* [Internet]. 2003 Mar;6(2):90–7. Available  
708 from: <https://linkinghub.elsevier.com/retrieve/pii/S1098301510601374>
- 709 36. Sousa F de OS, Medeiros KR de, Gurgel Júnior GD, Albuquerque PC de. Do  
710 normativo à realidade do Sistema Único de Saúde: revelando barreiras de acesso na  
711 rede de cuidados assistenciais. *Cien Saude Colet* [Internet]. 2014 Apr;19(4):1283–  
712 93. Available from: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1413-  
713 81232014000401283&lng=pt&tlng=pt](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232014000401283&lng=pt&tlng=pt)
- 714 37. Pot M, Kieusseyan N, Prainsack B. Not all biases are bad: equitable and inequitable  
715 biases in machine learning and radiology. *Insights Imaging* [Internet]. 2021 Dec  
716 10;12(1):13. Available from:  
717 <https://insightsimaging.springeropen.com/articles/10.1186/s13244-020-00955-7>  
718



hATTR-related ICD-10 codes: E85.0, E85.1 or E85.2.

wtATTR-related ICD-10 codes: E85, E85.3, E85.4, E85.8 or E85.9.

Specific cardiac-related ICD-10 codes: I50.0, I50.1, I50.9, I11.0, I42.0, I42.1, I42.2, I35.0, I44.1, I44.2, I42.5

General cardiac-related ICD-10 codes: I50.0, I50.1, I50.9, I51.7, G56.0, I44.0, I44.1, I44.2, I44.7, I48.0, N18.0, N18.8, N18.9, I42.5, I47.2

Figure 1

## Cardiac-related ICD-10 codes most frequent in hATTR-CM patients




Figure 2



## Cardiac-related ICD-10 codes most frequent in wtATTR-CM patients





Figure 3


## Annual hATTR-CM hospitalization rate from 2015 to 2021



\* Number of ATTR-CM-related hospitalizations per year, divided by the Brazilian population in each year x 100,000

Figure 4


# Annual wtATTR-CM hospitalization rate from 2015 to 2021



\* Number of ATTR-CM-related hospitalizations per year, divided by the Brazilian population in each year x 100,000

Figure 5

# Most frequent hATTR-CM reference related procedures



# Most frequent hATTR-CM-like related procedures





Figure 6

# Most frequent wtATTR-CM reference related procedures

medRxiv preprint doi: <https://doi.org/10.1101/2022.11.23.22282666>; this version posted November 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



# Most frequent wtATTR-CM reference related procedures




Figure 7